Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Children's Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Thioguanine
Drug: Vincristine Sulfate
Drug: Prednisone
Radiation: Prophylactic Cranial Irradiation

First Posted Date: 2009-03-20

Last Posted Date: 2021-04-27

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 104

Registration Number: NCT00866307

Locations: 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 25 locations

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Active, not recruiting

Conditions: Childhood Malignant Neoplasm

Interventions: Procedure: Cognitive Assessment
Other: Quality-of-Life Assessment

First Posted Date: 2008-10-15

Last Posted Date: 2024-08-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1200

Registration Number: NCT00772200

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Cardon Children's Medical Center, Mesa, Arizona, United States

and more 181 locations

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: cisplatin
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: methotrexate
Drug: zoledronic acid
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Biological: filgrastim
Drug: Mesna

First Posted Date: 2008-08-28

Last Posted Date: 2014-07-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 24

Registration Number: NCT00742924

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Southern California Permanente Medical Group, Downey, California, United States

and more 85 locations

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Recruiting

Conditions: Hematopoietic Cell Transplantation Recipient
Leukemia
Solid Tumor

Interventions: Procedure: Assessment of Therapy Complications
Other: Questionnaire Administration

First Posted Date: 2008-08-18

Last Posted Date: 2024-04-11

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 5000

Registration Number: NCT00736749

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 161 locations

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Gastrointestinal Mucositis
Malignant Neoplasm

Interventions: Other: Placebo
Drug: Palifermin

First Posted Date: 2008-08-06

Last Posted Date: 2018-08-07

Lead Sponsor: Children's Oncology Group

Registration Number: NCT00728585

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Phase 3

Completed

Conditions: Brain Tumor
Childhood Germ Cell Tumor
Sarcoma
Central Nervous System Tumor
Liver Cancer
Neuroblastoma
Ovarian Cancer
Extragonadal Germ Cell Tumor
Ototoxicity

Interventions: Drug: sodium thiosulfate
Procedure: examination

First Posted Date: 2008-07-16

Last Posted Date: 2023-11-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 131

Registration Number: NCT00716976

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 73 locations

Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Completed

Conditions: Recurrent Retinoblastoma
Extraocular Retinoblastoma
Intraocular Retinoblastoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2008-06-04

Last Posted Date: 2019-10-08

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 234

Registration Number: NCT00690469

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States

and more 49 locations

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Completed

Conditions: Ewing Sarcoma of Bone
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)
Unspecified Childhood Solid Tumor, Protocol Specific
Childhood Acute Lymphoblastic Leukemia
Childhood Soft Tissue Sarcoma
Childhood Rhabdomyosarcoma
Ewing Sarcoma
Wilms Tumor and Other Childhood Kidney Tumors

Interventions: Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2008-05-07

Last Posted Date: 2017-05-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 158

Registration Number: NCT00674193

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Miller Children's Hospital, Long Beach, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 35 locations

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

Not Applicable

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Other: pharmacological study
Procedure: dual x-ray absorptimetry

First Posted Date: 2008-05-07

Last Posted Date: 2020-04-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 107

Registration Number: NCT00673257

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 57 locations

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia

Interventions: Drug: Calaspargase Pegol-mknl
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Other: Pharmacological Study
Drug: Prednisone
Radiation: Radiation Therapy
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2008-05-02

Last Posted Date: 2021-04-27

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 166

Registration Number: NCT00671034

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

and more 24 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy